
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is positioned for success with their innovative approach to CNS drug delivery, strong pipeline of potential treatments, and expansion plans. The company's collaborations with leading research institutions and promising clinical trial results provide confidence in their ability to obtain FDA approval and bring their drugs to market in the near future. Financially, their strong cash position and low burn rate indicate stability and potential for future growth.
Bears say
NeOnc Technologies Hldgs is a clinical-stage biopharmaceutical company with promising drug candidates that target central nervous system diseases. However, there are multiple risks associated with its products and the competitive landscape, as well as potential challenges with pricing and reimbursement. This, along with the company's relatively small size and limited pipeline, leads to a negative outlook on its stock. Additionally, the company's financials show an increase in bridge loan expenses and no changes in operating assets and liabilities, indicating potential financial challenges ahead.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares